Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Epidermal Growth Factor Receptor. Found 24 abstracts

no pagination
Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia S. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Sep;34(25):2969-79.   PMCID: PMC5569693
Galloway TJ, Wirth LJ, Colevas AD, Gilbert J, Bauman JE, Saba NF, Raben D, Mehra R, Ma AW, Atoyan R, Wang J, Burtness B, Jimeno A. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr;21(7):1566-73.
Ali SM, Alpaugh RK, Buell JK, Stephens PJ, Yu JQ, Wu H, Hiemstra CN, Miller VA, Lipson D, Palmer GA, Ross JS, Cristofanilli M. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib. Clin Breast Cancer. 2014 Feb;14(1):e14-6.
Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, Devarajan K, Silverman JS, Tikhmyanova N, Skobeleva N, Pecherskaya A, Nasto RE, Sharma C, Jablonski SA, Serebriiskii IG, Weiner LM, Golemis EA. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Science signaling. 2010 Jan;3(140):ra67.   PMCID: PMC2950064
Cristofanilli M, Valero V, Mangalik A, Royce M, Rabinowitz I, Arena FP, Kroener JF, Curcio E, Watkins C, Bacus S, Cora EM, Anderson E, Magill PJ. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer. Clinical Cancer Research. 2010 Mar 15;16(6):1904-14.   PMCID: NIHMS352308
Li L, Quang TS, Gracely EJ, Kim JH, Emrich JG, Yaeger TE, Jenrette JM, Cohen SC, Black P, Brady LW. A Phase II study of anti-epidermal growth factor receptor radioimmunotherapy in the treatment of glioblastoma multiforme. J Neurosurg. 2010 Aug;113(2):192-8.   PMCID: not NIH funded
Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cellular signalling. 2009 Aug;21(8):1255-68.   PMCID: PMC2770888
Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 2009 Jul;19(5):929-33.   PMCID: PMC2722934
Astsaturov I, Cohen RB, Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer. Cancer Treat Res. 2008 Jan;139:135-52.
Borghaei H, Langer CJ, Millenson M, Ruth KJ, Litwin S, Tuttle H, Seldomridge JS, Rovito M, Mintzer D, Cohen R, Treat J. Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017. J Thorac Oncol. 2008 Nov;3(11):1286-92.
Langer CJ. Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer. 2008 Jun 15;112(12):2635-45.
Mehra R, Cohen RB, Harari PM. EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Current oncology reports. 2008 Mar;10(2):176-84.
Sengupta S, Jordan VC. Selective estrogen modulators as an anticancer tool: mechanisms of efficiency and resistance. Advances in experimental medicine and biology. 2008 Jan;630:206-19.
Ariazi EA, Kraus RJ, Farrell ML, Jordan VC, Mertz JE. Estrogen-related receptor alpha1 transcriptional activities are regulated in part via the ErbB2/HER2 signaling pathway. Molecular cancer research : MCR. 2007 Jan;5(1):71-85.
Astsaturov I, Cohen RB, Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer. Curr Cancer Drug Targets. 2007 Nov;7(7):650-65.
Denlinger CS, Cohen SJ. Progress in the development of prognostic and predictive markers for gastrointestinal malignancies. Current treatment options in oncology. 2007 Oct;8(5):339-51.
Forastiere AA, Burtness BA. Epidermal growth factor receptor inhibition in head and neck cancer--more insights, but more questions. J Clin Oncol. 2007 Jun;25(16):2152-5.
Langer CJ. Mind your elders: therapeutic implications of epidermal growth factor receptor inhibition in older patients with advanced non-small-cell lung cancer. J Clin Oncol. 2007 Mar;25(7):751-3.
Kim SH, Nakagawa H, Navaraj A, Naomoto Y, Klein-Szanto AJ, Rustgi AK, El-Deiry WS. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res. 2006 Nov;66(21):10415-24.
Damjanov N, Meropol NJ. Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?. Oncology (Williston Park). 2004 Apr;18(4):479-88; discussion 488, 493.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Epidermal Growth Factor Receptor

Epidermal Growth Factor Receptor drug therapy therapeutic use Squamous Cell Carcinoma Monoclonal Antibodies metabolism genetics Female Quinazolines Head and Neck Neoplasms Middle Aged antagonists & inhibitors Aged pathology methods Combined Modality Therapy Male Antineoplastic Agents Survival Rate Protein Kinase Inhibitors inhibitors Adult Prognosis Non-Small-Cell Lung Carcinoma Neoplasm Drug Resistance Lung Neoplasms adverse effects Estrogen Receptors administration & dosage Breast Neoplasms Treatment Outcome drug effects analysis antagonists & pharmacology Apoptosis Drug Delivery Systems 80 and over Aged Cisplatin erbB-2 Receptor Signal Transduction mortality Clinical Trials as Topic immunology Antineoplastic Combined Chemotherapy Protocols radiotherapy administration & dosage Neoplasm Metastasis Carboplatin Proto-Oncogene Proteins c-akt Maximum Tolerated Dose physiology Prospective Studies Progesterone Receptors secondary Gene Expression Profiling Next-generation sequencing Trastuzumab Inhibitors] ras Genes Mutation 0 (Quinazolines) Uterine Cervical Neoplasms Nitriles Radioimmunotherapy Protein Kinase C Age Factors Chemoradiotherapy blood Electrophoretic Mobility Shift Assay Multivariate Analysis Small Interfering RNA Cytotoxins Neoplasm Circulating Cells Postmenopause Hydroxamic Acids Proto-Oncogene Proteins p21(ras) Microsatellite Instability Presenilin-2 Immunohistochemistry Proportional Hazards Models Dacarbazine B7-H1 Antigen ai [Antagonists & Inhibitors] Protein-Tyrosine Kinase ai [Antagonists & Oncogenes Young Adult Protocols bcl-X Protein Biological Models Paclitaxel DNA-Binding Proteins therapy etiology biosynthesis 184475-35-2 (gefitinib) Transformed Cell Line myc Genes Phosphorylation ErbB-2 Receptor Brain Neoplasms Neoplastic Gene Expression Regulation Adenocarcinoma Radiotherapy Double-Blind Method Her2 Nuclear Receptor Coactivator 2 Thymidine Phosphorylase Human Heterologous Transplantation Cultured Tumor Cells Predictive Value of Tests Pemetrexed Protein Interaction Mapping Neoplasm Transplantation Carcinoembryonic Antigen Drug Discovery Alkylating Antineoplastic Agents Polymerase Chain Reaction Kaplan-Meiers Estimate Cell Cycle analogs & Antineoplastic Combined Chemotherapy Inflammatory Breast Neoplasms Quality of Life Genetic Transcription Drug Dose-Response Relationship Peptide Receptors 0 (erlotinib) Immunotherapy Gastrointestinal Neoplasms pharmacokinetics Epithelial Cells EC 2-7-1-112 (Protein-Tyrosine Kinase) Histone Deacetylases Biological Tumor Markers Disease-Free Survival Lymphatic Metastasis Hormone-Dependent Neoplasms STAT3 Transcription Factor 0 (Antineoplastic Agents) Mitogen-Activated Protein Kinase Kinases Neoplasm Staging Deoxycytidine Neoplastic Cell Transformation Medical Oncology Inbred BALB C Mice Mice
Last updated on Friday, August 14, 2020